SG Americas Securities LLC Acquires 189,004 Shares of Relay Therapeutics, Inc. $RLAY

SG Americas Securities LLC increased its holdings in shares of Relay Therapeutics, Inc. (NASDAQ:RLAY) by 591.7% during the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 220,949 shares of the company’s stock after purchasing an additional 189,004 shares during the period. SG Americas Securities LLC owned 0.13% of Relay Therapeutics worth $1,869,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Commodore Capital LP bought a new stake in shares of Relay Therapeutics in the 2nd quarter valued at about $46,191,000. TCG Crossover Management LLC acquired a new stake in Relay Therapeutics during the 3rd quarter worth about $9,450,000. Woodline Partners LP boosted its position in Relay Therapeutics by 448.4% in the first quarter. Woodline Partners LP now owns 1,518,561 shares of the company’s stock valued at $3,979,000 after buying an additional 1,241,657 shares during the last quarter. Bellevue Group AG boosted its holdings in shares of Relay Therapeutics by 11.6% in the 2nd quarter. Bellevue Group AG now owns 8,230,870 shares of the company’s stock valued at $28,479,000 after acquiring an additional 853,578 shares during the last quarter. Finally, Norges Bank purchased a new stake in Relay Therapeutics in the second quarter valued at $2,892,000. Hedge funds and other institutional investors own 96.98% of the company’s stock.

Analyst Upgrades and Downgrades

RLAY has been the topic of several recent research reports. Wells Fargo & Company upped their price objective on Relay Therapeutics from $15.00 to $17.00 and gave the stock an “overweight” rating in a research report on Tuesday, March 17th. Guggenheim lifted their price objective on Relay Therapeutics from $15.00 to $22.00 and gave the stock a “buy” rating in a report on Friday, March 13th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Relay Therapeutics in a research note on Friday, January 9th. Oppenheimer restated an “outperform” rating on shares of Relay Therapeutics in a research report on Monday, March 16th. Finally, Citizens Jmp upped their price objective on shares of Relay Therapeutics from $15.00 to $17.00 and gave the company a “market outperform” rating in a report on Tuesday, March 17th. One investment analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $18.00.

Relay Therapeutics Price Performance

NASDAQ RLAY opened at $12.54 on Monday. The company has a market cap of $2.24 billion, a P/E ratio of -7.74 and a beta of 1.57. The stock has a 50-day moving average of $9.47 and a two-hundred day moving average of $7.90. Relay Therapeutics, Inc. has a 1-year low of $1.77 and a 1-year high of $13.04.

Relay Therapeutics (NASDAQ:RLAY) last announced its earnings results on Thursday, February 26th. The company reported ($0.32) earnings per share for the quarter, topping the consensus estimate of ($0.38) by $0.06. The business had revenue of $7.00 million for the quarter, compared to analysts’ expectations of $4.34 million. On average, analysts anticipate that Relay Therapeutics, Inc. will post -2.55 EPS for the current fiscal year.

Insider Activity

In related news, CEO Sanjiv Patel sold 43,168 shares of the company’s stock in a transaction that occurred on Tuesday, January 6th. The shares were sold at an average price of $7.82, for a total transaction of $337,573.76. Following the sale, the chief executive officer directly owned 661,041 shares in the company, valued at approximately $5,169,340.62. This represents a 6.13% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Donald A. Bergstrom sold 18,895 shares of the firm’s stock in a transaction on Tuesday, January 27th. The shares were sold at an average price of $7.62, for a total transaction of $143,979.90. Following the completion of the sale, the insider owned 422,733 shares in the company, valued at $3,221,225.46. The trade was a 4.28% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 93,302 shares of company stock valued at $724,355 over the last three months. 4.87% of the stock is currently owned by corporate insiders.

About Relay Therapeutics

Relay Therapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of precision therapies for oncology. Headquartered in Cambridge, Massachusetts, the company was founded in 2016 with the goal of targeting dynamic protein motion using an integrated scientific platform. Relay Therapeutics leverages computational modeling, structural biology, and experimental validation to identify small-molecule drug candidates that modulate the behavior of disease-associated proteins.

The company’s core business activity centers on its proprietary drug-discovery engine, which combines high-performance computing—including molecular dynamics simulations—with advanced experimental techniques such as cryo-electron microscopy and biophysical screening.